Alogliptin/Pioglitazone (Liovel) Combination Tablets Survey on Long-term Use in Patients With Type 2 Diabetes Mellitus
The purpose of this survey is to examine the safety and efficacy of long-term use of
alogliptin/pioglitazone(Liovel) combination tablets in patients with type 2 diabetes mellitus
determined as warranting combination therapy with alogliptin benzoate and pioglitazone
The primary purpose of this study is to evaluate the efficacy of alogliptin 25 milligram (mg)
once daily compared to placebo when administered as monotherapy, or when added onto a
background of metformin alone, insulin alone, or a combination of metformin and insulin, as
measured by the glycosylated hemoglobin (HbA1c) change from Baseline at Week 26 in pediatric
participants with type 2 diabetes mellitus (T2DM).
Serving leading biopharmaceutical companies globally:
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.